**Press Release**

**Media Contacts:**

**IB Communications**

Tel +44 (0)20 89434685

orgenesis@ibcomms.agency

**Orgenesis CEO Vered Caplan featured in keynote series at INTERPHEX conference to discuss innovations in cell & gene therapy manufacturing**

**Germantown, MD, US, April 25, 2023 –** [Orgenesis Inc](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULG39lrK0X4AHKU6itUT5c-2FjwcgJiAVjL-2FjvFRoq42sForP3G_0v1WfzW3RyCyUmxOPcTd72nhp2tUCWdxq-2BDfwFXst-2F2aCPEFEoG1XfVfIkfPiSy0mEjkyHBzVnFoAkbS-2F5layLvGFGFbnAMRhXyFhnh4H5icF3LXEoJ5E8bTrpitPe8INE7xykEh1nUAnT4neD9NXYIApyGIquQG1ZRsuYZzKc9P3DkEbwEQv2XzDs4E9MuXsVxDwS-2Brq3uD4Ot8y97MXaDPgg7NSZfdDX5gPvs1HlwF8B8ehvTXZ2ylWsICF0NOY-2F23nGJ59E61dcPeKDomRgLCVjoDtz-2F0BpcWmqfZhqpYD1irJZdwL2EfRJ8cNK9kVy4oEMW8fV2gMIucbo9SfrLHbeEDx9-2BtVx2iv5oNSurpgkb-2B-2FVPwa632WWz-2BInu4EVn3i7FGjA6-2F2rapCUSL-2FlsEWPBID7C1XS9vmoUGwbKQ19txr5fhTm0Fvov6PbuE9uenVrVIDnXAJ7dPjj3eSA-3D-3D)[.](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULG39lrK0X4AHKU6itUT5c-2FjwcgJiAVjL-2FjvFRoq42sFoUDsx_0v1WfzW3RyCyUmxOPcTd72nhp2tUCWdxq-2BDfwFXst-2F2aCPEFEoG1XfVfIkfPiSy0mEjkyHBzVnFoAkbS-2F5layLvGFGFbnAMRhXyFhnh4H5icF3LXEoJ5E8bTrpitPe8INE7xykEh1nUAnT4neD9NXYIApyGIquQG1ZRsuYZzKc9P3DkEbwEQv2XzDs4E9MuXsVxDwS-2Brq3uD4Ot8y97MXaDPgg7NSZfdDX5gPvs1HlwF8B8ehvTXZ2ylWsICF0NOY-2F23nGJ59E61dcPeKDomRuPBtLpZkF2ZgEe8FtuiViinLmJZGDMKtqCOFZwf220FMEVyiRcrkawogcLY7bqyz7tuhF8zy7vtlm-2F6OzOURprpvHSDVLhX4tz6Z6vt2elJQfOCtqIxr3TYSDrk94qK0YjdvOUUw5UjMR-2F-2Fx3ez4n6iAXqVWOLQgieG48PT-2BvR-2B70fqxsp-2FAMc15aQoFB-2B-2FQw-3D-3D) (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announces Vered Caplan, CEO of Orgenesis, has been invited to participate in a keynote series, ‘[applied continuous and modular manufacturing innovations](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULEPGCQxCwbRS-2FyIIIW1PEkUjnbPIj9AJkSFDvMCfFHbhdkbREu0n2IE7-2FfT6BfzW0EZIWqFKV-2FjqSoHCHEsesXKoER-2BsIWWig1fJDTg5EfiXeG4BKqgI7y1x9lIguZYJNcII-2FleWwxAqe7sKDeV-2BTyhxsJeioedeZj01yvK5wZXKCC8OdYLFjcz7xwqVzFvsTWfWL49-2Fvz2qVa7MVJLXCa4RtsXJY-2Fc7BlB8QbhS-2BX2tJLA5_0v1WfzW3RyCyUmxOPcTd72nhp2tUCWdxq-2BDfwFXst-2F2aCPEFEoG1XfVfIkfPiSy0mEjkyHBzVnFoAkbS-2F5layLvGFGFbnAMRhXyFhnh4H5icF3LXEoJ5E8bTrpitPe8INE7xykEh1nUAnT4neD9NXYIApyGIquQG1ZRsuYZzKc9P3DkEbwEQv2XzDs4E9MuXsVxDwS-2Brq3uD4Ot8y97MXaDPgg7NSZfdDX5gPvs1HlwF8B8ehvTXZ2ylWsICF0NOY-2F23nGJ59E61dcPeKDomRtmjt-2FNMPUg0DKbjWp7a1oRo8iBk5BuUyRyGzjE0Py94bCfHt55I8ow6VR0cF7iI9mkb2-2FsUNA-2Fv4Lx0ajKJjb-2FZnfWopMmP-2Bv263Y-2F98h0udb9u8m8nrawXoZaqFvPX2dg-2Fv-2Ffge0Eq7acgQxgTUXudrFqeu1sWZtwrWms2dSYMbYCoD-2FJhZjrxwN2DGPD9-2Fg-3D-3D),’ where she plans to discuss the latest innovations at the Company’s POCare Services subsidiary, Morgenesis, LLC, including its Orgenesis Mobile Processing Units and Labs (OMPULs), which provide decentralized autologous cell and gene therapies to patients at lower costs.

The keynote series will be delivered at the [INTERPHEX conference](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULEPGCQxCwbRS-2FyIIIW1PEkX0A8AB81zW8DKkaNnnljDXUsI-2BNqn6Z3eM2WRDDu-2BTIA-3D-3DIrPf_0v1WfzW3RyCyUmxOPcTd72nhp2tUCWdxq-2BDfwFXst-2F2aCPEFEoG1XfVfIkfPiSy0mEjkyHBzVnFoAkbS-2F5layLvGFGFbnAMRhXyFhnh4H5icF3LXEoJ5E8bTrpitPe8INE7xykEh1nUAnT4neD9NXYIApyGIquQG1ZRsuYZzKc9P3DkEbwEQv2XzDs4E9MuXsVxDwS-2Brq3uD4Ot8y97MXaDPgg7NSZfdDX5gPvs1HlwF8B8ehvTXZ2ylWsICF0NOY-2F23nGJ59E61dcPeKDomRkwUAmsC9Se7OBn4emgxhqoiF3EzplxKpW-2FUA9uLUaDORCPeL5-2FWF59w5TAKKVVdC3DK-2BOwcToi0UglIM6XzODPa8nqs2LoOhKE216-2BzVLRxeo4yalMoZXi4RsFKHlZCf5QQQLdoo6g1d21-2F0cjQlKaKVYDAp6x5KpB8Tm-2BApJ6O3-2F6K-2FeuudxHK-2FAsdDeuDWQ-3D-3D). This event covers the pharmaceutical product development lifecycle, between April 25-27, 2023, at the Javits Centre in New York. The [Keynote Series](https://click.agilitypr.delivery/ls/click?upn=UbtWP9mxrAkz4-2Bt4ix9ULEPGCQxCwbRS-2FyIIIW1PEkUjnbPIj9AJkSFDvMCfFHbhdkbREu0n2IE7-2FfT6BfzW0EZIWqFKV-2FjqSoHCHEsesXKoER-2BsIWWig1fJDTg5EfiXeG4BKqgI7y1x9lIguZYJNcII-2FleWwxAqe7sKDeV-2BTyhxsJeioedeZj01yvK5wZXKCC8OdYLFjcz7xwqVzFvsTWfWL49-2Fvz2qVa7MVJLXCa4RtsXJY-2Fc7BlB8QbhS-2BX2t1kZW_0v1WfzW3RyCyUmxOPcTd72nhp2tUCWdxq-2BDfwFXst-2F2aCPEFEoG1XfVfIkfPiSy0mEjkyHBzVnFoAkbS-2F5layLvGFGFbnAMRhXyFhnh4H5icF3LXEoJ5E8bTrpitPe8INE7xykEh1nUAnT4neD9NXYIApyGIquQG1ZRsuYZzKc9P3DkEbwEQv2XzDs4E9MuXsVxDwS-2Brq3uD4Ot8y97MXaDPgg7NSZfdDX5gPvs1HlwF8B8ehvTXZ2ylWsICF0NOY-2F23nGJ59E61dcPeKDomRmyUwllp9RRpy07NmvCtE6zJpbN3E7Iv1IqyboWv8N2ut7W-2Bwdg-2Bl1b9KYFE6I6-2B6RfB25CbEue1TPCKfGxGr7oEBDyFCfpwxe3wDo8pubnh-2Bc4zAdg-2FJv-2Flc1pSUWs0nU8i6sCW0SrLxNGOEPhoN-2BUahcdfqPvGvYNE6nR1i8fuR7ccmL5-2BZacnSIC0SVGf4w-3D-3D) will be held on the Innovation Stage, Booth #1378 on Wednesday, Apr 26, between 1:15 pm and 3:00 pm Eastern Time.

The keynote series will cover how the bio and pharma industries can build on the successes of continuous manufacturing (CM) for the advanced manufacture of pharmaceuticals. These successes have included buy-in and support from regulatory authorities, including the FDA.

**About Orgenesis**

Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. [www.orgenesis.com](https://click.agilitypr.delivery/ls/click?upn=x0SJT0-2BQwcXxaFugdr-2BQ6bSc-2FI967kMxaJJpA0TQpKG8pjwJBeQMBy0b3WEF8iub_X6w_0v1WfzW3RyCyUmxOPcTd72nhp2tUCWdxq-2BDfwFXst-2F2aCPEFEoG1XfVfIkfPiSy0mEjkyHBzVnFoAkbS-2F5layLvGFGFbnAMRhXyFhnh4H5icF3LXEoJ5E8bTrpitPe8INE7xykEh1nUAnT4neD9NXYIApyGIquQG1ZRsuYZzKc9P3DkEbwEQv2XzDs4E9MuXsVxDwS-2Brq3uD4Ot8y97MXaDPgg7NSZfdDX5gPvs1HlwF8B8ehvTXZ2ylWsICF0NOY-2F23nGJ59E61dcPeKDomRo1XDoBFojv0hIp-2BY0D1oPMhpz3D-2BAjfMTyjki-2BSTbBedvYD8-2F43gJ5RA8NRpcEVxSmG2-2Fd1-2BtQdWHx4X7v5Vy-2FOCdnoJdY0OKz9sPXw22veub-2BOkjti4DnWcFerYxUZQqa4Ch7G50Wvula2FNC79gH-2FIlk4mcAmQkUngpumb0H46ctshowTpBTCyDuFcZ6M7g-3D-3D).

***Notice Regarding Forward-Looking Statements***

*This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Se**curities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, our ability to manage potential disruptions as a result of the COVID-19 pandemic, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our POCare strategy, our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.*